retatrutide trial dose Breaking: New data just released. TRIUMPH-1 study results on the triple agonist. Eli Lilly's clinical trial on Retatrutide (triple agonist compound). 80 weeks. Phase 3 data. The results: At 12mg Retatrutide Dosage & Dosing Guide:

The highest dose of orforglipron helped patients lose on average 10.5% of their weight, or 22.9 pounds, on average at 72 weeks, compared to 2.2% weight loss among those who took a placebo

Hassan N, Rashad M, Elleithy E, Sabry Z, Ali G, Elmosalamy S

Pubmed 17(1):175 Landrigan PJ, Goldman LR (2011) Childrens vulnerability to toxic chemicals: a challenge and opportunity to strengthen health and environmental policy

Estos resultados concuerdan con las conclusiones de Tekeli [ 30 ]

But this protection is not automatic

Semaglutide (sold under the brand names Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) are synthetic versions of GLP-1